pl
en
Country
pl
Language
en
Prof. Mohamad Mohty, Ph.D
Mohamad Mohty France
  • Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France)

Prof. Mohamad Mohty, Ph.D

Mohamad Mohty is full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and University Pierre & Marie Curie (Paris, France).

Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.

Professor Mohty’s is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents.

He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.

Professor Mohty is currently president of the European Society for Blood and Marrow Transplantation (EBMT). He serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, International Society for Experimental Hematology, and EBMT.

Professor Mohty has published more than 430 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals.

He also serves as Editor-in-Chief of the journal Bone Marrow Transplantation, as Associate Editor for Leukemia, European Journal of Haematology and Blood Cancer Journal, as member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as Blood, The Lancet, and Nature Reviews.

Conducted lectures